MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line...
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line...
Company honored in its commitment to patients and families living with mitochondrial disease; invites the community to walk with BPGbio...
Engagement Will Expand Daré’s Engagement in Advancing Women’s Health Innovation and Provide Insights into One of the Most Significant Unmet...
New Alignment Health study shows nearly 2 in 5 seniors who experience loneliness say it’s impacting their health, 1 in...
NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or...
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and...
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is...
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million...
Healthcare as the World’s Most Strategic Investment: KFSHRC CEO Calls for Global Collaboration at C3 Japan Summit H.E. Dr. Majid...
IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical...
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by...
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor...
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in...
NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- As the American Association of Christian Counselors (AACC) World Conference in Nashville...
SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies...
U.S. Fast Track designation underscores the strength of the alnodesertib clinical data generated to date and the high degree of...
Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading...
CARBIOS has reduced its operating expenses and has a strong cash position of €72 million as of June...